A Phase IIIb, Long-Term, Open-Label, Multi-Center, Extension Study Designed to Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD) [EXTENSION OF 700025883]
Latest Information Update: 28 Apr 2017
Price :
$35 *
At a glance
- Drugs Methylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions; Registrational
- Sponsors Shire
- 14 Feb 2013 New trial record